Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 4, 2014, Pages 755-764

  Zhao, Ying Zheng ^a,b   Li, Xing ^c   Lu, Cui Tao ^a   Lin, Min ^a   Chen, Li Juan ^a   Xiang, Qi ^d   Zhang, Ming ^a   Jin, Rong Rong ^a   Jiang, Xi ^a   Shen, Xiao Tong ^a   Li, Xiao Kun ^a   Cai, Jun ^e  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Hangzhou Xiasha Hospital   (China)

^d JINAN UNIVERSITY   (China)

^e University of Louisville School of Medicine   (United States)

Author keywords

BFGF; Gelatin nanostructured lipid carriers; Hemiparkinsonian; Nose to brain drug delivery

Indexed keywords

AMINO ACIDS; BIOACTIVITY; DRUG DELIVERY; EMULSIFICATION; NANOPARTICLES; PHOSPHOLIPIDS;

BASIC FIBROBLAST GROWTH FACTOR; BFGF; BIOLOGICALLY ACTIVE COMPOUNDS; GELATIN NANOPARTICLES; HEMIPARKINSONIAN; MONOAMINE NEUROTRANSMITTERS; NANOSTRUCTURED LIPID CARRIERS; WATER-IN-WATER EMULSIONS;

RATS;

DRUG CARRIER; FIBROBLAST GROWTH FACTOR 2; GELATIN NANOSTRUCTURED LIPID CARRIER; MONOAMINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; GELATIN; LIPID; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TOLERABILITY; EMULSION; FREEZE DRYING; NANOENCAPSULATION; NONHUMAN; NOSE MUCOSA; OLFACTORY BULB; PARKINSONISM; PARTICLE SIZE; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; RAT; THERAPY EFFECT; TOXICITY TESTING; ZETA POTENTIAL; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; INTRANASAL DRUG ADMINISTRATION; PARKINSON DISEASE, SECONDARY; PATHOPHYSIOLOGY;

ADMINISTRATION, INTRANASAL; ANIMALS; CORPUS STRIATUM; DRUG CARRIERS; FIBROBLAST GROWTH FACTOR 2; GELATIN; LIPIDS; NANOPARTICLES; OLFACTORY BULB; PARKINSON DISEASE, SECONDARY; RATS;

EID: 84900322139     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.10.009     Document Type: Article

References (50)

1. Lochhead J.J., Thorne R.G. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012, 64(7):614-628.
2. Costantino H.R., Illum L., Brandt G., Johnson P.H., Quay S.C. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007, 337(1-2):1-24.
3. Vyas T.K., Shahiwala A., Marathe S., Misra A. Intranasal drug delivery for brain targeting. Current Drug Delivery 2005, 2(2):11.
4. Alsarra I.A., Hamed A.Y., Mahrous G.M., El Maghraby G.M., Al-Robayan A.A., Alanazi F.K. Mucoadhesive polymeric hydrogels for nasal delivery of acyclovir. Drug Development and Industrial Pharmacy 2009, 35(3):352-362.
5. Alsarra I.A., Hamed A.Y., Alanazi F.K. Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation. Drug Delivery 2008, 15(5):313-321.
6. Arumugam K., Subramanian G., Mallayasamy S., Averineni R., Reddy M., Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharma 2008, 58(3):287-297.
7. Mistry A., Stolnik S., Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009, 379(1):146-157.
8. Doijad R.C., Manvi F.V., Godhwani D.M., Joseph R., Deshmukh N.V. Formulation and targeting efficiency of cisplatin engineered solid lipid nanoparticles. Indian Journal of Pharmaceutical Sciences 2008, 70(2):203-207.
9. Howells D.W., Porritt M.J., Wong J.Y.F., Batchelor P.E., Kalnins R., Hughes A.J., et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 2000, 166(1):127-135.
10. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. NeuroReport 1999, 10(3):557-561.
11. Tooyama I., Kawamata T., Walker D., Yamada T., Hanai K., Kimura H., et al. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. Neurology 1993, 43:372-376.
12. Tooyama I., McGeer E.G., Kawamata T., Kimura H., McGeer P.L. Retention of basic fibroblast growth factor immunoreactivity in dopaminergic neurons of the substantia nigra during normal aging in humans contrasts with loss in Parkinson's disease. Brain Res 1994, 656(1):165-168.
13. Baquet Z.C., Bickford P.C., Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. The Journal of Neuroscience 2005, 25(26):6251-6259.
14. Timmer M., Cesnulevicius K., Winkler C., Kolb J., Lipokatic-Takacs E., Jungnickel J., et al. Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion. The Journal of Neuroscience 2007, 27(3):459-471.
15. Rangasamy S.B., Soderstrom K., Bakay R.A.E., Kordower J.H. Chapter 13 - neurotrophic factor therapy for Parkinson's disease. Progress in Brain Research 2010, 184:237-264. Elsevier. B. Anders, M.A. Cenci (Eds.).
16. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37(12):1553-1561.
17. Edelman E.R., Nugent M.A., Karnovsky M.J. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci 1993, 90(4):1513-1517.
18. Deguchi Y., Naito T., Yuge T., Furukawa A., Yamada S., Pardridge W.M., et al. Blood-brain barrier transport of 125I-labeled basic fibroblast growth factor. Pharm Res 2000, 17(1):63-69.
19. Whalen G.F., Shing Y., Folkman J. The fate of intravenously administered bFGF and the effect of heparin. Growth Factors 1989, 1(2):157-164.
20. Tobío M., Gref R., Sánchez A., Langer R., Alonso M.J. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 1998, 15(2):270-275.
21. Varshosaz J., Eskandari S., Tabbakhian M. Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design. Pharm Dev Technol 2010, 15:89-96.
22. Varshosaz J., Tabbakhian M., Mohammadi M.Y. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. Journal of Liposome Research 2010, 20(4):286-296.
23. Jiang Y., Wei N., Lu T., Zhu J., Xu G., Liu X. Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 2011, 172:398-405.
24. Xiang Q., Xiao J., Zhang H., Zhang X., Lu M., Zhang H., et al. Preparation and characterisation of bFGF-encapsulated liposomes and evaluation of wound-healing activities in the rat. Burns 2011, 37(5):886-895.
25. Decressac M., Ulusoy A., Mattsson B., Georgievska B., Romero-Ramos M., Kirik D., et al. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain 2011, 134(8):2302-2311.
26. Kemeny S., Dery D., Loboda Y., Rovner M., Lev T., Zuri D., et al. Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein. PLoS ONE 2012, 7(7):e38837.
27. van den Berg M.P., Verhoef J.C., Romeijn S.G., Merkus F.W.H.M. Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm 2004, 58(1):131-135.
28. Wang Z.-L., Cheng S.-M., Ma M.-M., Ma Y.-P., Yang J.-P., Xu G.-L., et al. Intranasally delivered bFGF enhances neurogenesis in adult rats following cerebral ischemia. Neurosci Lett 2008, 446(1):30-35.
29. Modi G., Pillay V., Choonara Y.E., Ndesendo V.M.K., du Toit L.C., Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 2009, 88(4):272-285.
30. Bondì M.L., Fontana G., Carlisi B., Giammona G. Preparation and characterization of solid lipid nanoparticles containing cloricromene. Drug Delivery 2003, 10(4):245-250.
31. Das S., Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011, 12(1):62-76.
32. Patel S., Chavhan S., Soni H., Babbar A.K., Mathur R., Mishra A.K., et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 2011, 19(6):468-474.
33. Katakam M., Bell L.N., Banga A.K. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 1995, 84(6):713-716.
34. Salama H.A., Mahmoud A.A., Kamel A.O., Abdel Hady M., Awad G.A.S. Phospholipid based colloidal poloxamer-nanocubic vesicles for brain targeting via the nasal route. Colloids Surf B: Biointerfaces 2012, 100:146-154.
35. Vandelli M.A., Rivasi F., Guerra P., Forni F., Arletti R. Gelatin microspheres crosslinked with d, l-glyceraldehyde as a potential drug delivery system: preparation, characterisation, in vitro and in vivo studies. Int J Pharm 2001, 215(1-2):175-184.
36. Zhao Y.-Z., Li X., Lu C.-T., Xu Y.-Y., Lv H.-F., Dai D.-D., et al. Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy. Acta Diabetol 2012, 49(4):315-325.
37. Di Colo G., Zambito Y., Zaino C. Polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetration-enhancing properties, mechanism of action, safety issues. J Pharm Sci 2008, 97(5):1652-1680.
38. Zaki N.M., Awad G.A., Mortada N.D., Abd ElHady S.S. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci 2007, 32(4-5):296-307.
39. Gizurarson S. Animal models for intranasal drug delivery studies. A review article. Acta Pharmaceutica Nordica 1990, 2(2):105-122.
40. Lin H., Gebhardt M., Bian S., Kwon K.A., Shim C.-K., Chung S.-J., et al. Enhancing effect of surfactants on fexofenadine·HCl transport across the human nasal epithelial cell monolayer. Int J Pharm 2007, 330(1-2):23-31.
41. Charlton S., Whetstone J., Fayinka S., Read K., Illum L., Davis S. Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model. Pharm Res 2008, 25(7):1531-1543.
42. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000, 11(1):1-18.
43. Thorne R.G., Frey W.H. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001, 40(12):907-946.
44. Thorne R.G., Emory C.R., Ala T.A., Frey Ii W.H. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 1995, 692(1-2):278-282.
45. Date I., Yoshimoto Y., Imaoka T., Miyoshi Y., Gohda Y., Furuta T., et al. Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging. Brain Res 1993, 621(1):150-154.
46. Hsuan S.-L., Klintworth H.M., Xia Z. Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways. The Journal of Neuroscience 2006, 26(17):4481-4491.
47. Takayama H., Ray J., Raymon H.K., Baird A., Hogg J., Fisher L.J., et al. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nature Medicine 1995, 1:53-58.
48. Laham R.J., Chronos N.A., Pike M., Leimbach M.E., Udelson J.E., Pearlman J.D., et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study. J Am Coll Cardiol 2000, 36(7):2132-2139.
49. Zhang L., Lu C.-T., Li W.-F., Cheng J.-G., Tian X.-Q., Zhao Y.-Z., et al. Physical characterization and cellular uptake of propylene glycol liposomes in vitro. Drug Development and Industrial Pharmacy 2012, 38(3):365-371.
50. Altar C.A., Marien M.R., Marshall J.F. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J Neurochem 1987, 48(2):390-399.